Low superoxide dismutase and catalase is associated malondialdehyde and ischemia modified albumin in patients with Non-ST elevated myocardial infarction (NSTEMI)

Non-ST elevated myocardial infarction (NSTEMI) diagnosis is difficult when the electrocardiography (ECG) normal and troponin parameters are slightly higher than the normal reference range. This study aimed to assess the IMA (ischemia modified albumin), MDA (malondialdehyde), SOD (superoxide dismutase), and catalase in patients with NSTEMI. The present study included 55 patients with NSTEMI and 55 healthy subjects prospectively. IMA, MDA, SOD, and catalase levels were measured from venous blood obtained from each patient within twelve hours after the onset of symptoms. Differences between the two groups were evaluated with Student's unpaired t-test for parameters with a normal distribution. IMA (3.14 ± 0.06 vs. 1.49 ± 0.03) and MDA (3.14 ± 0.06 vs. 1.49 ± 0.03) were higher, and SOD (1.10 ± 0.03 vs. 2.31 ± 0.02) and catalase (0.54 ± 0.02) vs. 0.22 ± 0.02) were lower in NSTEMI patients than control subjects. There was a significant correlation among IMA, MDA, SOD and catalase. Our data reveal that levels of MDA and IMA were increased, and SOD and catalase levels were decreased significantly in patients with NSTEMI. Blood concentrations of oxidant and antioxidant parameters could assess the oxidative state in patients with NSTEMI

PDF

___

1. Pantazopoulos I, Papadimitriou L, Dontas I, Demestiha T, Iakovidou N, Xanthos T. Ischaemia modified albumin in the diagnosis of acute coronary syndromes. Resuscitation 2009; 80: 306-310. 2. Karimian A, Farajnia S, Ghojazadeh M, Khaki-Khatibi F. The association between PAI-1 gene promoter polymorphism and serum serpin E1, MDA, and Hs-CRP levels in coronary artery disease. International Cardiovascular Research Journal 2016; 10: 129-134. 3. Ito T, Fujita H, Tani T, Ohte N. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent. Atherosclerosis 2015; 239: 311-317. 4. Ikenaga H, Kurisu S, Kono S, Sumimoto Y, Watanabe N, Shimonaga T, et al. Impact of Malondialdehyde-Modified Low-Density Lipoprotein on Tissue Characteristics in Patients With Stable Coronary Artery Disease–Integrated Backscatter-Intravascular Ultrasound Study–. Circulation Journal 2016; 80: 2173-2182. 5. Halliwell B, Gutteridge JM. Free radicals in biology and medicine. Oxford University Press, page; 160-165, 670-673, USA; 2015. 6. Díaz-Araya G, Nettle D, Castro P, Miranda F, Greig D, Campos X, et al. Oxidative stress after reperfusion with primary coronary angioplasty: lack of effect of glucose-insulinpotassium infusion. Critical care medicine 2002; 30: 417-421. 7. Bar–Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report. The Journal of emergency medicine 2000; 19: 311-315. 8. Young I, Trimble E. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Annals of clinical biochemistry 1991; 28: 504-508. 9. Elstner E, Youngman R, Obwald W. Superoxide dismutase. Methods of enzymatic analysis 1983; 3: 293-302. 10. Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clinica chimica acta 1991; 196: 143-151. 11. Amioka N, Miyoshi T, Otsuka H, Yamada D, Takaishi A, Ueeda M, et al. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Journal of cardiology 2019; 74: 258-266. 12. Gholikhani-Darbroud R, Khaki-Khatibi F, Mansouri F, Hajahmadipoorrafsanjani M, Ghojazadeh M. Increased circulatory levels of ischemia modified albumin, protein carbonyl, malondialdehyde and total antioxidant capacity as prognostic biomarkers for non-STsegment elevation myocardial infarction: a ROC curve analysis. Crescent Journal of Medical and Biological Sciences 2018; 5: 350- 357. 13. Serdar Z, Aslan K, Dirican M, Sarandöl E, Yeşilbursa D, Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clinical biochemistry 2006; 39: 794- 803. 14. Ito T, Fujita H, Tani T, Sugiura T, Ohte N. Increased circulating malondialdehydemodified low-density lipoprotein levels in patients with ergonovine-induced coronary artery spasm. International Journal of Cardiology 2015; 184: 475-480. 15. Gammoudi I, Dandana A, Chahed H, Ferchichi S, Ernez S, Miled A. Evaluation of oxidative stress among coronary patients. immuno-analyse & biologie specialisee 2013; 28: 39-42. 1. Pantazopoulos I, Papadimitriou L, Dontas I, Demestiha T, Iakovidou N, Xanthos T. Ischaemia modified albumin in the diagnosis of acute coronary syndromes. Resuscitation 2009; 80: 306-310.

2. Karimian A, Farajnia S, Ghojazadeh M, Khaki-Khatibi F. The association between PAI-1 gene promoter polymorphism and serum serpin E1, MDA, and Hs-CRP levels in coronary artery disease. International Cardiovascular Research Journal 2016; 10: 129-134.

3. Ito T, Fujita H, Tani T, Ohte N. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent. Atherosclerosis 2015; 239: 311-317.

4. Ikenaga H, Kurisu S, Kono S, Sumimoto Y, Watanabe N, Shimonaga T, et al. Impact of Malondialdehyde-Modified Low-Density Lipoprotein on Tissue Characteristics in Patients With Stable Coronary Artery Disease–Integrated Backscatter-Intravascular Ultrasound Study–. Circulation Journal 2016; 80: 2173-2182.

5. Halliwell B, Gutteridge JM. Free radicals in biology and medicine. Oxford University Press, page; 160-165, 670-673, USA; 2015.

6. Díaz-Araya G, Nettle D, Castro P, Miranda F, Greig D, Campos X, et al. Oxidative stress after reperfusion with primary coronary angioplasty: lack of effect of glucose-insulinpotassium infusion. Critical care medicine 2002; 30: 417-421.

7. Bar–Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report. The Journal of emergency medicine 2000; 19: 311-315.

8. Young I, Trimble E. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Annals of clinical biochemistry 1991; 28: 504-508.

9. Elstner E, Youngman R, Obwald W. Superoxide dismutase. Methods of enzymatic analysis 1983; 3: 293-302.

10. Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clinica chimica acta 1991; 196: 143-151.

11. Amioka N, Miyoshi T, Otsuka H, Yamada D, Takaishi A, Ueeda M, et al. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Journal of cardiology 2019; 74: 258-266.

12. Gholikhani-Darbroud R, Khaki-Khatibi F, Mansouri F, Hajahmadipoorrafsanjani M, Ghojazadeh M. Increased circulatory levels of ischemia modified albumin, protein carbonyl, malondialdehyde and total antioxidant capacity as prognostic biomarkers for non-STsegment elevation myocardial infarction: a ROC curve analysis. Crescent Journal of Medical and Biological Sciences 2018; 5: 350- 357.

13. Serdar Z, Aslan K, Dirican M, Sarandöl E, Yeşilbursa D, Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clinical biochemistry 2006; 39: 794- 803.

14. Ito T, Fujita H, Tani T, Sugiura T, Ohte N. Increased circulating malondialdehydemodified low-density lipoprotein levels in patients with ergonovine-induced coronary artery spasm. International Journal of Cardiology 2015; 184: 475-480.

15. Gammoudi I, Dandana A, Chahed H, Ferchichi S, Ernez S, Miled A. Evaluation of oxidative stress among coronary patients. immuno-analyse & biologie specialisee 2013; 28: 39-42.